University of Florida Health Proton Therapy Institute, Jacksonville, Florida.
University of Florida Health Proton Therapy Institute, Jacksonville, Florida.
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):422-434. doi: 10.1016/j.ijrobp.2016.02.038. Epub 2016 Feb 16.
To report clinical outcomes in patients treated with image guided proton therapy (PT) for localized prostate cancer.
The medical records of 1327 men were reviewed. Each man was enrolled on an outcomes tracking study. Dual enrollment on a prospective clinical trial was allowed. Each patient was treated for localized prostate cancer with PT at our institution between 2006 and 2010. Ninety-eight percent of patients received 78 Gy (radiobiological equivalent [RBE]) or higher; 18% received androgen deprivation therapy (ADT). The 5-year freedom from biochemical progression (FFBP), distant metastasis-free survival, and cause-specific survival rates are reported for each risk group. Data on patient-reported quality of life and high-grade toxicities were prospectively collected and reported. A multivariate analysis was performed to identify clinical predictors of biochemical failure and urologic toxicity.
The median follow-up time was 5.5 years. The 5-year FFBP rates were 99%, 94%, and 74% in low-risk, intermediate-risk, and high-risk patients, respectively. The actuarial 5-year rates of late grade 3+ Common Terminology Criteria for Adverse Events, version 4.0, gastrointestinal (GI) and genitourinary (GU) toxicity were 0.6% and 2.9%, respectively. Multivariate analysis showed a significant correlation between grade 3+ GU toxicity and pretreatment prostate reductive procedures (P<.0001), prostate volume (P=.0085), pretreatment α-blockers (P=.0067), diabetes (P=.0195), and dose-volume histogram parameters (P=.0208). The median International Prostate Symptom Scores pretreatment scores and scores at 5 years after treatment were 7 and 7, respectively. The mean Expanded Prostate Cancer Index Composite (EPIC) scores significantly declined for sexual summary for patients not receiving ADT (from 67 to 53) between baseline and 5 years.
Image guided PT provided excellent biochemical control rates for patients with localized prostate cancer. The actuarial rates of high-grade toxicity were low after PT. From pretreatment to 5 years of follow-up, a significant decline was found only in mean EPIC sexual summary scores. Prospective clinical studies are needed to determine the comparative effectiveness of PT and other radiation treatment strategies.
报告接受图像引导质子治疗(PT)的局限性前列腺癌患者的临床结果。
回顾了 1327 名男性的病历。每位男性均参加了一项结果跟踪研究。允许同时参加前瞻性临床试验。我们机构于 2006 年至 2010 年间对每位局限性前列腺癌患者进行 PT 治疗。98%的患者接受了 78Gy(生物等效[RBE])或更高剂量;18%的患者接受了雄激素剥夺治疗(ADT)。报告了每个风险组的 5 年无生化进展(FFBP)、远处转移无生存和特定原因生存的情况。前瞻性收集和报告了患者报告的生活质量和高级别毒性的数据。进行了多变量分析以确定生化失败和泌尿系统毒性的临床预测因素。
中位随访时间为 5.5 年。低危、中危和高危患者的 5 年 FFBP 率分别为 99%、94%和 74%。晚期 3+级常见不良事件术语标准 4.0(CTCAE),胃肠道(GI)和泌尿生殖系统(GU)毒性的 5 年累积发生率分别为 0.6%和 2.9%。多变量分析显示,3+级 GU 毒性与预处理前列腺缩小手术(P<0.0001)、前列腺体积(P=0.0085)、预处理α受体阻滞剂(P=0.0067)、糖尿病(P=0.0195)和剂量-体积直方图参数(P=0.0208)之间存在显著相关性。治疗前的中位国际前列腺症状评分(IPSS)和治疗后 5 年的评分分别为 7 和 7。未接受 ADT 的患者的前列腺癌指数综合评分(EPIC)的性综合评分从基线到 5 年显著下降(从 67 降至 53)。
图像引导 PT 为局限性前列腺癌患者提供了优异的生化控制率。PT 后的高级别毒性发生率较低。从治疗前到 5 年随访期间,仅发现 EPIC 性综合评分的平均评分显著下降。需要前瞻性临床研究来确定 PT 和其他放射治疗策略的比较效果。